Procedure file

Basic information

RSP - Resolutions on topical subjects	2020/2837(RSP)	Procedure completed
Resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 87460 × MON 89034 × MIR162 × NK603 and genetically modified maize combining two, three or four of the single events MON 87427, MON 87460, MON 89034, MIR162 and NK603, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council Subject 3.10.09.06 Agro-genetics, GMOs		

Key players

European Parliament	Committee responsible	Rapporteur	Appointed
	ENVI Environment, Public Health and Food Safety		19/10/2020
		epp PIETIKÄINEN Sirpa	19/10/2020
			19/10/2020
			19/10/2020
		S&D SIDL Günther	
		METZ Tilly	
		NI EVI Eleonora	

Key events

11/11/2020	Results of vote in Parliament		
11/11/2020	Decision by Parliament	T9-0293/2020	Summary
11/11/2020	End of procedure in Parliament		

Technical information

Procedure reference	2020/2837(RSP)
Procedure type	RSP - Resolutions on topical subjects
Procedure subtype	Resolution on implementing act or powers
Legal basis	Rules of Procedure EP 112-p2

Stage reached in procedure	Procedure completed
Committee dossier	ENVI/9/04443

Documentation gateway					
Motion for a resolution		B9-0347/2020	11/11/2020	EP	
Text adopted by Parliament, single reading		T9-0293/2020	11/11/2020	EP	Summary
Commission response to text adopted in plenary		SP(2021)32	22/03/2021	EC	

Resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 87460 × MON 89034 × MIR162 × NK603 and genetically modified maize combining two, three or four of the single events MON 87427, MON 87460, MON 89034, MIR162 and NK603, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council

The European Parliament adopted by 526 votes to 142, with 18 abstentions, a resolution objecting to the draft Commission implementing decision authorising the placing on the market of products containing genetically modified maize MON 87427 × MON 87460 × MON 89034 × MIR162 × NK603 and genetically modified maize combining two, three or four of the single events MON 87427, MON 87460, MON 89034, MIR162 and NK603.

The application for marketing authorisation was submitted by Monsanto Europe N.V., on behalf of Monsanto Corporation, USA, to the competent authority of the Netherlands on 28 October 2016. On 3 July 2019, the European Food Safety Authority (EFSA) adopted an opinion in favour of the application.

Main comments from the Member States

Members pointed out that Member States have sent numerous critical comments to EFSA on the fact:

- that potential interactions with environmental conditions, which may affect the transgenic protein content in the plant, are not taken into account;

- that there are still unresolved questions regarding safety and possible toxicity, and that the evaluation does not take into account herbicide residues and glyphosate metabolites;

- that there are concerns regarding the use of the antimicrobial resistant gene.

In addition, the applicant has not provided experimental data for the currently unauthorised 14 sub-combinations of the stacked GM maize.

Lack of evaluation of herbicide residues and degradation products

Members pointed out that herbicide-tolerant genetically modified crops are leading to an increase in the use of complementary herbicides, in particular due to the emergence of herbicide-tolerant weeds. It can therefore be expected that the stacked GM will be repeatedly exposed to higher rates of glyphosate, which could lead to an increase in the amount of residues in the crops.

In addition, there are still questions about the carcinogenicity of glyphosate. In 2015, the International Agency for Research on Cancer of the World Health Organization has, contrary to the EFSA and the European Chemicals Agency (ECHA), classified glyphosate as a probable carcinogen to humans.

Members also noted that:

- according to several studies, side effects have been observed that may affect the immune system following exposure to Bt proteins and that some Bt proteins may have adjuvant properties, meaning that they could increase the allergenicity of other proteins that they come into contact with;

- stacked GM maize produces the NPTII protein that confers resistance to a range of antibiotics, including neomycin and kanamycin, which the WHO classifies as critically important for human and veterinary medicine. Austria has formally opposed the placing on the market of stacked GM maize because of the inclusion of this antibiotic resistance marker gene.

Undemocratic decision-making

Members recalled that in the vote held on 15 September 2020, the Standing Committee on the Food Chain and Animal Health delivered no opinion, meaning that the authorisation was not supported by a qualified majority of Member States.

The Commission has repeatedly deplored the fact that decisions on the authorisation of GMOs continue to be adopted by the Commission without a qualified majority of Member States being in favour, which is very much the exception for product authorisations as a whole, but has become the norm for decisions on GM food and feed authorisations.

Recommendations

Based on these considerations, Parliament considered that the Commission's implementing decision was not compatible with EU law. Consequently, it called on the Commission to:

- withdraw its draft implementing decision;

- make progress on the development of sustainability criteria, with full involvement of the Parliament;

- take into account the EU's obligations under international agreements, such as the Paris Climate Agreement, the UN Convention on Biological Diversity and the UN sustainable development goals;

- ceases to authorise GMOs, whether for cultivation or for use as food or feed, where no opinion is given by the Member States in the Appeal Committee;

- not authorise herbicide-tolerant GM crops until the health risks from residues have been thoroughly investigated on a case-by-case basis;

- to take full account of the risk assessment of the use of complementary herbicides and their residues in the risk assessment of herbicide-tolerant GM crops, irrespective of whether the crop concerned is intended to be grown in the EU or imported into the EU as food or feed;

- allowing sub-combinations of stacked events only if they have been thoroughly evaluated by EFSA on the basis of complete data submitted by the applicant.

EFSA is called on to further develop and systematically use methods that permit the identification of unintended effects of stacked GM events.